Vedolizumab Clearance and Its Role in Inflammatory Bowel Disease Remission
Author Information
Author(s): Marković Srđan, Kralj Đorđe, Svorcan Petar, Knežević Ivanovski Tamara, Odanović Olga, Obradović Sanja, Homšek Ana, Jovanović Marija, Savić Rada, Vučićević Katarina M., Mager Donald E.
Primary Institution: University Hospital Medical Center “Zvezdara”, Belgrade, Serbia
Hypothesis
The study investigates the variability in vedolizumab trough levels and pharmacokinetic parameters to assess their relationship with clinical and endoscopic outcomes in inflammatory bowel disease patients.
Conclusion
Vedolizumab clearance is a more reliable predictor of remission in inflammatory bowel disease patients than trough concentration.
Supporting Evidence
- Vedolizumab clearance increased by 26.4% in patients previously treated with anti-TNFα agents.
- VDZ trough concentration was not a statistically significant predictor of remission.
- Clinical remission was associated with endoscopic remission.
- Fecal calprotectin and vedolizumab clearance were significant predictors of endoscopic remission.
Takeaway
This study shows that how quickly the drug vedolizumab is cleared from the body can help doctors know if a patient with inflammatory bowel disease will get better.
Methodology
A retrospective, monocentre study analyzing 116 trough vedolizumab concentrations from 106 patients using population pharmacokinetic modeling.
Potential Biases
Single-centre study may introduce biases related to local clinical practices and patient demographics.
Limitations
The study's retrospective design and limited sample size may restrict the generalizability of the findings.
Participant Demographics
The cohort included 62 ulcerative colitis patients and 44 Crohn's disease patients, with a mean age of approximately 49.76 years and a gender distribution of 51.9% male.
Statistical Information
P-Value
0.05
Confidence Interval
0.12–1.0
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website